Gilead Sciences IncGILD:NSQ

100.30
0.81 / 0.80%
11.54m
34.87%
0.7113
Close in USDToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Nov 26 2014 21:15 GMT.

Consensus recommendation

As of Nov 22, 2014, the consensus forecast amongst 30 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy13
Outperform10
Hold6
Underperform0
Sell0
No opinion0

Research Reports

S&P Capital IQ – STARS Reports
Ford Investor Services, Inc.
Directors Deals Ltd.

Share price forecast

The 23 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 127.00, with a high estimate of 170.00 and a low estimate of 81.00. The median estimate represents a 26.62% increase from the last price of 100.30. View Full Financials

High+69.5 %170.00
Med+26.6 %127.00
Low-19.2 %81.00

Dividends

Dividend information is not available for Gilead Sciences Inc. View Full Financials

Earnings history & estimates

On Oct 28, 2014, Gilead Sciences, Inc. reported 3rd quarter 2014 earnings of 2.05 per share. This result exceeded the 1.92 consensus of the 25 analysts covering the company and exceeded last year's 3rd quarter results by 1.53.
The next earnings announcement is expected on Feb 02, 2015. View Full Interim Financials

Average growth rate+55.30%

Gilead Sciences, Inc. reported annual 2013 earnings of 2.04 per share on Feb 04, 2014.
The next earnings announcement from Gilead Sciences, Inc. is expected the week of Feb 02, 2015. View Full Annual Financials

Average growth rate+10.28%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

Gilead Sciences Inc. had 3rd quarter 2014 revenues of 6.04bn. This bettered the 5.99bn consensus of the 22 analysts covering the company. This was 7.55% below the prior year's 3rd quarter results. View Full Interim Financials

Average growth rate+23.88%

Gilead Sciences Inc. had revenues for the full year 2013 of 11.20bn. This was 15.45% above the prior year's results. View Full Annual Financials

Average growth rate+12.51%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.